Fighting for Cancer Patients
Oncology
Our scientists and oncologists strive to give patients improved treatment outcomes and a life beyond cancer by developing therapies that elevate the standards of care.
Building on expertise to tackle the toughest cancers
Our scientific research has led to critical discoveries in the treatment of blood cancer. Building upon our strong commitment to patients and existing leadership in blood cancers, we are now boldly expanding our footprint in solid tumors. Our robust portfolio in blood cancers and solid tumors is comprised of first-of-its kind treatments and an advancing pipeline of more than 20 investigational assets that are designed to tackle some of the most difficult-to-treat cancers in the world.
Research interests
We focus on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We achieve this through multiple modalities such as immuno-oncology approaches, tumor antigen targeting, and taking advantage of specific tumor dependencies. Our research interests include:
- Identifying and targeting mechanisms that allow tumor cells to proliferate and survive, including under-explored forms of regulated cell death, such as necroptosis and ferroptosis
- Investigating how to re-energize T cells so that they can retain their fitness and continue to destroy tumor cells
- Advancing the use of Antibody Drug Conjugates (ADCs) to target and deliver potent toxins and targeted agents to cancer cells
- Creating new technologies to improve the efficacy of bispecific biologics in treating both solid tumors and blood cancers, enabling the development of therapies with highly targeted potential
- Innovating in the field of targeted protein degradation by designing protein degraders that bind to a protein of interest and trigger its proteasomal degradation
- Developing CAR-T cell therapies that attack cancers with healthy donor immune cells engineered to target and kill tumor cells while being resistant to host immune system rejection
Oncology focus areas
We are focusing on finding answers that transform the way cancer are treated. We want to find better, longer-lasting results across blood cancers and solid tumors. Our culture of curiosity drives us to uncover new solutions.
Blood cancers
Blood cancer is a disease that impacts blood forming tissues (such as bones marrow) and inhibits the body's ability to fight off infection. Leukemia, lymphoma, and myeloma are the most common forms of blood cancer that are seen in patients.
Solid tumors
Despite recent innovations, people living with solid tumors are still in need of more options. As survival rates remain low, patients often run out of options after multiple cycles of treatment, emphasizing the urgent need to further improve patient care and outcomes.
We are advancing an innovative solid tumor portfolio that tackles some of the most difficult-to-treat cancers. Our approach is to target novel anti-cancer pathways, using different modalities such as antibody-drug conjugates (ADCs) designed to target protein biomarkers, which are over-expressed across various tumor types, to deliver potent cancer-killing agents called ‘payloads’ to those cells, and immuno-oncology (IO) approaches, that use the body's immune system to fight cancer.
Popular pages
External links
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2024 AbbVie Inc. North Chicago, Illinois, U.S.A.
